Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides - Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS

Chromatographic speed classification for liquid chromatography using average theoretical peak time (ATPT)

BACKGROUND

The development of analytical techniques in the field of liquid chromatography has brought new frontiers in performance and analytical speed for the technique. The proper evaluation of the analytical boundaries achieved with those developments was not addressed in the literature, since different liquid chromatography (LC) techniques have not yet received any classification regarding their chromatographic speed. Defining chromatographic analysis speed based simply on analysis time is an outdated concept since it is sample and analyte-dependent. In this context, the application of the Average Theoretical Peak Time concept (ATPT) is proposed as a unified metric for chromatographic speed classification.

RESULTS

This metric was evaluated using PCA analysis in a group of more than 50 publications, which generated the classification of LC methods in normal, high, hyper, and ultra-high-speed separations using ATPT. Normal speed (ATPT values greater than 18000 ms/peak) was found in HPLC, nano-LC, SFC, and CEC methods. Therefore, high-speed methods (ATPT values between 4000 and 18000 ms/peak) were found in UHPLC techniques, while LC × LC methods presented higher ATPT values between 1000 and 4000 ms/peak being classified as hyper-speed separations. ATPT can also be used as an optimization parameter, since older methods show higher ATPT values, while recent published papers show lower values of this metric. This behavior is justified due to the improvement of the LC methods over the years.

SIGNIFICANCE

This work fulfills the gap in chromatographic definitions and metrics, regarding analytical speed in one-dimensional and multidimensional liquid chromatographic techniques and shows that ATPT metrics is a robust parameter that can be used to classify the separation speed as well as a metric to evaluate the LC Method optimization. It also corrects the historical application of separation time as a metric for chromatographic speed.

Evaluation of PepT1 (SLC15A1) Substrate Characteristics of Therapeutic Cyclic Peptides

The human peptide transporter hPepT1 (SLC15A1), physiologically transporting dipeptides and tripeptides generated during food digestion, also plays a role in the uptake of small bioactive peptides and peptide-like drugs. Moreover, it might be addressed in prodrug strategies of poorly absorbed drugs. We hypothesised that the cyclic drug peptides octreotide and pasireotide could be substrates of this transporter because their diameter can resemble the size of dipeptides or tripeptides due to their strong structural curvature and because they reach the systemic circulation in Beagle dogs. For investigating possible hPepT1 substrate characteristics, we generated and characterised a CHO-K1 cell line overexpressing SLC15A1 by transfection and selection via magnetic beads. Possible inhibition of the uptake of the prototypical substrate Gly-Sar by octreotide and pasireotide was screened, followed by quantifying the uptake of the cyclic peptides in cells overexpressing SLC15A1 compared with the parental cell line. Although inhibition of Gly-Sar uptake was observed, uptake of octreotide and pasireotide was not increased in SLC15A1 overexpressing cells, indicating a lack of transport by hPepT1. Our data clearly indicate that octreotide and pasireotide are nonsubstrate inhibitors of hPepT1 and that their oral bioavailability cannot be explained by absorption via hPepT1.

Intact plasma quantification of the large therapeutic lipopeptide bulevirtide

Bulevirtide is a first-in-class entry inhibitor of the hepatitis B and hepatitis delta virus blocking the sodium/bile acid co-transporter NTCP, and was recently approved for the treatment of hepatitis D as a priority medicine (prime) in an accelerated assessment by the European Medicines Agency. It is a very large lipopeptide comprising 47 amino acids in its sequence and a myristoylation at the N-terminus. For support of clinical development, we established highly sensitive plasma quantification assays using 100 μL of plasma, spanning concentrations of 0.1 to 100 ng/mL and 1 to 1000 ng/mL with the option to measure ten-fold diluted samples up to 10,000 ng/mL. Quantification was performed with UPLC-MS/MS measurements after extraction with protein precipitation. Both assays were fully validated according to the pertinent guidelines of the FDA and EMA, including incurred sample reanalyses and cross-validation using clinical study samples.